Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 12Neoplasm Metastasis 6Glioblastoma 4Triple Negative Breast Neoplasms 3Brain Neoplasms 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Carcinoma, Non-Small-Cell Lung 2Treatment for Metastatic or Locally Advanced Cervical Cancer 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Pre-menopausal Breast Cancer 1Non-Small Cell Lunch Cancer 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Locally Advanced Solid Tumor 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Rituximab 90Cyclophosphamide 30Lenalidomide 28Bendamustine Hydrochloride 24Prednisone 20Vincristine 19obinutuzumab 17Doxorubicin 16fludarabine 14ibrutinib 13tazemetostat 9idelalisib 9Deoxycholic Acid 9parsaclisib 8Prednisolone 8zanubrutinib 7venetoclax 7tofacitinib 7tisagenlecleucel 5pembrolizumab 5ofatumumab 5ibritumomab tiuxetan 5duvelisib 5Gemcitabine 5Bortezomib 5durvalumab 4aflibercept 4R-CHOP protocol 4Methylprednisolone 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Follicular × NVP-BKM120 × Clear all
NCT01693614 2018-09-28

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

Novartis

Phase 2 Completed
72 enrolled 15 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡